Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
The CAPRISA 004 trial demonstrated the safety and a 39% efficacy of a 1% tenofovir (TFV) gel for the prevention of HIV-1 acquisition in young African women. It was subsequently shown that women assigned to the TFV arm who became infected had higher viral loads, slower anti-HIV-1 antibody avidity mat...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Division of Virology
2017
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|